Sonova SOON.SW
Sonova is a Swiss leader in hearing solutions, designing, developing, and marketing hearing aids, cochlear implants, and related accessories through brands such as Phonak and Unitron. Sonova shows solid financial health (ND/EBITDA 1.18) and a robust competitive moat (ROE 20.52%, gross margin 73.72%), although its valuation is demanding (P/E 27.44) and free cash flow conversion is weak (41.12%). Momentum is positive (99th percentile in 52-week range).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Sonova is a Swiss leader in hearing solutions, designing, developing, and marketing hearing aids, cochlear implants, and related accessories through brands such as Phonak and Unitron. Sonova shows solid financial health (ND/EBITDA 1.18) and a robust competitive moat (ROE 20.52%, gross margin 73.72%), although its valuation is demanding (P/E 27.44) and free cash flow conversion is weak (41.12%). Momentum is positive (99th percentile in 52-week range).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.3 |
| Quality / Moat | 7.3 |
| Valuation | 4.5 |
| Dividend | 6.3 |
| Momentum | 6.2 |
| Risk & Context | 5.2 |
OVERALL SCORE: 6.1/10
Context and risks
Moderate governance/regulatory risk in Switzerland. No material exposure to rates, oil, or geopolitics; the hearing aid business is defensive and does not depend on shipping routes or commodities.
News considered in the analysis
- Bernstein unveils top European medtech stock picks to buy for H2 — Recomendación de analista de primer nivel; puede atraer flujo de compra, pero no cambia los fundamentales.
- IART vs. SONVY: Which Stock Is the Better Value Option? — Comparativa genérica de valor entre dos valores, sin información nueva sobre Sonova.
- IART or SONVY: Which Is the Better Value Stock Right Now? — Listículo de comparación de valor, sin información nueva.
- Sonova Holding AG (SONVF) Full Year 2026 Earnings Call Highlights: Strong Growth Amidst Market ... — Resultados anuales con crecimiento sólido; refuerza la tesis de calidad, aunque el mercado ya lo ha descontado parcialmente.
- GMED vs. SONVY: Which Stock Is the Better Value Option? — Comparativa genérica de valor, sin información nueva.
Verdict: Hold; quality is high but valuation already discounts good expectations, and free cash flow conversion deserves monitoring.
Main risk: Free cash flow conversion of 41.12% is low for the sector, which could limit reinvestment capacity or dividend sustainability if growth decelerates.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →